In addition to the use of HSCs in stem cell transplantation for hematologic reconstitution, many clinicians are investigating the use of HSCs for the treatment of ischemic diseases such as critical limb ischemia, chronic myocardial ischemia, and traumatic brain injury.

 While these clinical uses of HSCs are still investigational, promising data have been generated.  Fate believes that its proven success in modulating key stem cell properties, including those that enhance HSC homing, may be highly relevant to improving patient outcomes in these other clinical settings.  Fate’s enhanced HSC program (eHSCs) is designed to generate next generation, best-in-class stem cell therapies.